# NOTE: To learn more about the fields, hover over their names.
definitions:
  common:
    processing_level: minor
    presentation:
      topic_tags:
        - Tuberculosis
tables:
  expenditure:
    variables:
      exp_cpp_dstb:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Average cost of drugs spent per patient starting first-line TB treatment, excluding buffer
          stock (US Dollars)
      exp_cpp_mdr:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Average cost of drugs spent per patient starting second-line treatment for MDR-TB, excluding
          buffer stock (US Dollars)
      exp_cpp_xdr:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Average cost of drugs spent per patient starting pre-XDR/XDR-TB treatment, excluding buffer
          stock (US Dollars)
      exp_cpp_tpt:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Average cost of drugs spent per person starting TB preventive treatment, excluding buffer
          stock (US Dollars)
      exp_lab:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Actual expenditure on laboratory infrastructure, equipment and supplies (US Dollars)
      rcvd_lab:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received for laboratory infrastructure, equipment and supplies (US Dollars)
      exp_staff:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Actual expenditure on National TB Programme staff (central unit staff and subnational TB
          staff)  (US Dollars)
      rcvd_staff:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received for National TB Programme staff (central unit staff and subnational TB
          staff)  (US Dollars)
      exp_fld:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Actual expenditure on drugs to treat drug-susceptible TB (US Dollars)
      rcvd_fld:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received for drugs to treat drug-susceptible TB (US Dollars)
      exp_prog:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Actual expenditure on programme costs to treat drug-susceptible TB (US Dollars)
      rcvd_prog:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received for programme costs to treat drug-susceptible TB (US Dollars)
      exp_sld:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Actual expenditure on drugs to treat drug-resistant TB (US Dollars)
      rcvd_sld:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received for drugs to treat drug-resistant TB (US Dollars)
      exp_mdrmgt:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Actual expenditure on programme costs to treat drug-resistant TB (US Dollars)
      rcvd_mdrmgt:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received for programme costs to treat drug-resistant TB (US Dollars)
      exp_tpt:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Actual expenditure on drugs for TB preventive treatment (US Dollars)
      rcvd_tpt:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received for drugs for TB preventive treatment (US Dollars)
      exp_tbhiv:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Actual expenditure on collaborative TB/HIV activities (US Dollars)
      rcvd_tbhiv:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received for collaborative TB/HIV activities (US Dollars)
      exp_patsup:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Actual expenditure on patient support (US Dollars)
      rcvd_patsup:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received for patient support (US Dollars)
      exp_orsrvy:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Actual expenditure on operational research and surveys (US Dollars)
      rcvd_orsrvy:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received for operational research and surveys (US Dollars)
      exp_oth:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Actual expenditure on all other budget line items (US Dollars)
      rcvd_oth:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received for all other budget line items (US Dollars)
      exp_tot:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Total actual expenditure (US Dollars)
      rcvd_tot:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Total funding received for all budget line items (US Dollars)
      rcvd_tot_domestic:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received from domestic sources, including loans (US Dollars)
      rcvd_tot_gf:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received from the Global Fund to Fight AIDS, Tuberculosis and Malaria (US Dollars)
      rcvd_tot_usaid:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received from USAID (US Dollars)
      rcvd_tot_grnt:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Funding received from other sources (US Dollars)
      rcvd_tot_sources:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Total funding received from all sources (US Dollars)
      hcfvisit_dstb:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Typical number of visits to a health facility after diagnosis for patients starting first-line
          TB treatment
      hcfvisit_mdr:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Typical number of visits to a health facility after diagnosis for patients starting MDR-TB/XDR-TB
          treatment
      hospd_dstb_prct:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Estimated percentage of patients starting first-line TB treatment that are hospitalized
          (%)
      hospd_mdr_prct:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Estimated percentage of patients starting MDR-TB/XDR-TB treatment that are hospitalized
          (%)
      hospd_dstb_dur:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Estimated average duration of stay if patients starting first-line TB treatment are hospitalized
          (days)
      hospd_mdr_dur:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Estimated average duration of stay if patients starting MDR-TB/XDR-TB treatment are hospitalized
          (days)
      hosp_type_mdr:
        unit: ""
        display:
          numDecimalPlaces: 0
        description_from_producer: Type of facility most often used if MDR-TB patients are hospitalized
